Clinical Trials Browser

Phase 4 × methylnaltrexone × Head & Neck × Clear all

NCT06162377 2025-12-17

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Phase 4 Recruiting

Squamous Cell Carcinoma of Head and Neck